Executive Team

Dr. Martin Gleave

Executive Director, Vancouver Prostate Centre
Chief Executive Officer, PC-TRiADD
Distinguished Professor and Head, Department of Urologic Sciences, UBC
BC Leadership Chair in Prostate Cancer Research

 

Dr. Gleave (MD, FRCSC, FACS) is a clinician-scientist and urologic surgeon. His major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr. Gleave established a role for clusterin as a cancer-related cell survival protein involved in treatment resistance and developed an inhibitor, designated OGX-011, which improved efficacy of hormone- and chemo-therapies in prostate and other cancer models. He is the scientific founder of OncoGenex Pharmaceuticals Inc.

Dr. Larry Goldenberg

Director of Development and Supportive Care, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, UBC
Stephen A. Jarislowski Chair in Urologic Sciences at VGH

 

Dr. Goldenberg (CM, OBC, MD, FRCSC, FACS, FCAHS) is a urologic surgeon and clinical scientist with an international reputation for excellence in prostate cancer research and treatment. His current research involves the evaluation of the role of multiparametric MRI in prostate cancer, the potential use of focal therapy, patient education, daVinci robotic prostatectomy and novel treatments for benign prostatic hyperplasia. He has been recognized for his contributions to health care by being inducted into the Order of British Columbia and the Order of Canada.

Dr. Paul Rennie

Director, Laboratory Research, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, UBC

 

Dr. Rennie is a PhD research scientist. His current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. He is also studying prostate-specific elements of gene promoters and working to develop lenti and herpes virus-based vectors as a targeting vehicle for delivery and prostate-specific expression of genes that can control or kill prostate tumour cells.

Dr. Graeme Boniface

Chief Operating Officer, Vancouver Prostate Centre
Chief Operating Officer, PC-TRiADD

Dr. Boniface joined the Prostate Centre in 2008 as COO, after more than 20 years in drug development in both the academic and private industry sectors. Prior to joining our Centre, he was Senior Director of Clinical Research at QLT Inc. where he oversaw the clinical development of the company’s drug platform in Oncology, Urology, Dermatology, and Endocrinology indications. Trials conducted by his team have lead to successful regulatory marketing approvals by the US FDA, Canadian, and European agencies.

Brian Shankaruk

Chief Financial Officer, Vancouver Prostate Centre
Chief Financial Officer, PC-TRiADD

Brian Shankaruk has over 25 years experience in the financial field.  For 20 years prior to joining the Centre, Brian worked in the insurance and financial services industry, focusing on Canadian and US statutory government reporting.  Brian studied accounting at UBC and received his Certified General Accountant designation in 1990.  Much of Brian’s recent work has involved systems design and implementation, especially as it relates to operations management and government regulations.

Dr. Kim Chi

Associate Director, Clinical Research, Vancouver Prostate Centre
Senior Research Scientist, Vancouver Prostate Centre
Medical Director, Clinical Trials Unit, BC Cancer Agency
Chair, Genitourinary Systemic Group, BC Cancer Agency
Professor, Department of Medicine, UBC

 

Dr. Chi is a medical oncologist with the BC Cancer Agency who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research. Dr. Chi's research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs.  This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He holds peer reviewed grant funding from the National Cancer Institute of Canada (NCIC), The U.S. Department of Defense, and the Prostate Cancer Research Foundation of Canada. Nationally, he has led a number of multi-centre phase I and II clinical trials, and is a co-chair on an NCIC-Clinical Trials Group phase III trial evaluating neoadjuvant docetaxel and hormone therapy prior to radiation therapy for patients with localized, high-risk prostate cancer. Internationally, he has contributed to numerous trials, and is a co-chair on a multi-centre, multi-national phase III trial evaluating DN101 (a high dose formulation of calcitriol) in patients with hormone refractory prostate cancer.

Dr. Chi is the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre, which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies. This is the largest cancer clinical trials unit in British Columbia and directly employs 30 full time staff. Under his guidance, the not-for-profit Clinical Trials Unit has been able to almost double patient accrual to trials, becoming a self-sustaining growth operation with revenues projected at over $3.3 million for fiscal year 2007-2008.

An Assistant Professor with the Department of Medicine at the University of British Columbia, Dr. Chi was appointed Chair of the Genitourinary  Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at www.bccancer.bc.ca) and securing access to new therapies through the province’s health care system.

Dr. Chi is an Executive Committee Member of the Genitourinary Disease Site for the National Cancer Institute – Clinical Trials Group (NCIC-CTG)/Canadian Uro-Onology Group (CUOG), and the Chair of the sub-site Advanced Prostate group. This committee and group are responsible for developing, undertaking, organizing and coordinating the genitourinary and prostate cancer trials respectively undertaken by investigators at a national cooperative group level.  Dr. Chi is also an Executive Committee Member of the Investigational New Drug Site for the NCIC-CTG which is responsible for developing, undertaking, organizing and coordinating early phase trials across the NCIC-CTG disease sites.

Dr. Colin Collins

Senior Research Scientist, Vancouver Prostate Centre
Director, Laboratory for Advanced Genome Analysis, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia

 

Dr Collins is a Senior Research Scientist at the Vancouver Prostate Centre and a Director of The Laboratory for Advanced Genome Analysis (LAGA). In addition, he is an associate adjunct professor at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and a visiting scientist at Lawrence Berkeley National Laboratory. He has held positions at Lawrence Livermore National Laboratory and Lawrence Berkeley National Laboratory at UCSF.  His current research is best described as translational genomics where mathematics, genomics, computer science, and clinical science converge in diagnostics and therapeutics.

His work as a member of the UCSF Prostate SPORE has resulted in identification of a suite of DNA based biomarkers that show promise for predicting a patient’s risk of progression and metastasis. Dr. Collins invented and patented End Sequence Profiling (ESP) the forerunner of modern paired-end sequencing. ESP is a sequence-based method for determining the physical structure, complexity, and mutation load of tumor genomes and for direct detection of fusion genes and transcripts. Dr Collins is now integrating array-based technologies and next generation sequencing technologies to radically cut costs and make very large-scale tumor genome projects and personalized oncology a reality in the near term.

Dr. Collins is on the Scientific Advisory Boards of the International Drug Discovery Science and Technology Conference (China), BIT Life Sciences Gene Conference (China), Genome British Columbia’s Molecular Lymphoma project, and Combimatrix Molecular Diagnostics. He is on the Organizing Committee of the Advances In Genome Biology and Technology (AGBT) Conference and serves on the editorial board of the Open Pathology Journal. His collaborations are extensive and global resulting in approximately 80 peer-reviewed manuscripts.  He holds multiple patents, and has received numerous awards including the California Cancer Research Programs Cornelius L. Hopper Scientific Achievement Award for Innovation

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Step Up Challenge fundraiser: Feb 19 in Vancouver

The annual Step Up Challenge, raising funds for Prostate Cancer Canada, takes place in Vancouver on February 19. Once again, VPC researchers are taking on the challenge to climb 375 flights of stairs; click here to sponsor our team.

BMO Vancouver Marathon, May 7: Prostate Cancer Foundation BC fundraiser

Prostate Cancer Foundation BC has a fundraising page for participants in the BMO Vancouver Marathon on May 7th.  You can make a donation by clicking here, or contact PCF-BC for more information of how to help at prostatebceventsattelus [dot] net.

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.

Movember